Form 4: MBX Biosciences CEO Executes Routine Tax-Related Stock Sale

MBX Biosciences CEO P. Kent Hawryluk sold 607 shares of common stock to satisfy tax obligations related to the vesting of restricted stock units.

Summary

• P. Kent Hawryluk, President and CEO of MBX Biosciences, Inc., sold 607 shares of common stock on May 6, 2026.
• The transaction was executed at a weighted average price of $29.54 per share, with individual prices ranging from $29.23 to $29.88.
• Following the transaction, the CEO maintains direct ownership of 727,667 shares and indirect ownership of 486,777 shares held in a revocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a change in management sentiment regarding the company's outlook.

Positives

• The sale was non-discretionary and conducted solely to cover tax withholding obligations associated with the vesting of equity awards.

Negatives

• Reduction in direct equity holdings by the CEO, though the volume is immaterial relative to total holdings.

Risks

• Market volatility affecting the value of remaining equity holdings.
• Regulatory risks associated with compliance under Section 16 of the Securities Exchange Act.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The reporting person disclaims beneficial ownership of trust-held shares except to the extent of any pecuniary interest therein.

Industry Context

StockSavvy.ai notes that this is a standard 'sell-to-cover' transaction common in the biotechnology sector, where executives frequently liquidate small portions of vested equity to satisfy mandatory tax withholding requirements.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance.
• The use of a mandatory sell-to-cover agreement is consistent with industry-wide practices for publicly traded biotech firms.

Related Party Transactions

• Shares held by the P. Kent Hawryluk Revocable Trust, of which the Reporting Person serves as trustee.

Stakeholder Impact

• Minimal impact on shareholders as the sale was small and mandatory for tax purposes.

Next Steps

• Continued monitoring of insider transactions for significant changes in ownership stakes.

Key Dates

Keywords

MBX Biosciences, Insider Trading, Form 4, Executive Compensation, Equity Vesting, Biotech